Core Viewpoint - Silver诺医药-B (02591) has successfully listed, with an initial share price of HKD 18.68, raising approximately HKD 634.7 million from the issuance of 36.5564 million shares, and has seen a significant increase of 285.44% to HKD 72 per share at the time of reporting [1] Company Overview - Silver诺医药 focuses on providing high-quality pharmaceuticals for patients with metabolic diseases [1] - The company's pipeline includes the core product, Isupatide α, which is under development for treating obesity and metabolic dysfunction-related fatty liver disease (MASH), along with five other candidates in preclinical stages [1] Product Development - The first pipeline product, Isupatide α (formerly known as Supatide, brand name: Yinuo Qing), is expected to receive approval from the National Medical Products Administration of China in January 2025, making it the first domestically developed humanized long-acting GLP-1 receptor agonist in China [1] - The company is also developing Isupatide α for indications related to weight loss and metabolic dysfunction-related fatty liver disease, addressing significant unmet treatment needs in these areas [1]
新股首日 | 银诺医药-B(02591)首挂上市 早盘高开285.44% 核心产品依苏帕格鲁肽α今年1月获批上市